Compare Halliburton Company (HAL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Zimmer Biomet Holdings Inc — how do they compare? Halliburton Company trades at $32.5 (market cap $27.14B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HAL | ZBH | |
|---|---|---|
Market Cap | $27.14B | $16.95B |
Volume | 11,258,156 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $42.98 | $103.98 |
52-Week Low | $21.82 | $79.58 |
Typical Hold Time | 89 Days | 89 Days |
Enterprise Value | $33.29B | $24.02B |
Dividend Yield | 2.09% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.55, up 2.52% today, amid a generally bearish technical outlook. The stock shows solid fundamentals with a P/E of 17.05 and net income margin of 7.16%, though revenue declined slightly in 2025. Recent news highlights expansion in Venezuela and a new contract in Cyprus, signaling growth initiatives. Earnings have beaten estimates for three consecutive quarters, with Q3 2026 results pending.
The investment outlook is supported by strong analyst consensus (73% buy ratings) and a $43.11 price target, implying significant upside. Key risks include exposure to oil price volatility and execution challenges in international expansions. Cash flow trends show variability, with 2025 net cash flow negative but projected to improve in 2026.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
